Skip to content
WELCOME10 — 10% OFF YOUR FIRST ORDER  ·  FREE SHIPPING OVER $300 CAD  ·  COA ON REQUEST
Research Comparison

FOXO4-DRI vs NAD+

FOXO4-DRI and NAD+ are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.

Shared research areas:Cellular Longevity
Class46-residue all-D retro-inverso peptideDinucleotide coenzyme — not a peptide
Molecular weight5358.2 g/mol663.43 g/mol
CAS number2460055-10-9Not assigned / not specified
Purity spec≥99%≥99%
Research areasCellular LongevityCellular Longevity, Metabolic
Primary diluentSterile water (USP grade)Sterile or bacteriostatic water
Working windowCommonly worked with for 2-3 weeks at 2-8 °C in bacteriostatic water.Short: commonly worked with within 1–2 weeks at 2–8 °C, and prepared fresh where accuracy matters.
Lead degradation routeDeamidation at the Asn-Gly motif in the sequence — the fastest-deamidating dipeptide in peptide chemistry.Alkaline hydrolysis — NAD+ degrades rapidly above neutral pH. This is the single most important handling fact about the compound.
Freeze–thawAliquot on first reconstitution and freeze aliquots once; avoid repeated freeze–thaw cycles, which concentrate the peptide and salts at the ice interface.Aliquot immediately after reconstitution. NAD+ solutions tolerate freezing but each thaw restarts the hydrolytic clock.
Light sensitivityContains a tryptophan residue, which is susceptible to photo-oxidation — store in the dark.Protect from light; the nicotinamide ring is photo-sensitive.

How they actually differ

Comparing the two: FOXO4-DRI is 46-residue all-d retro-inverso peptide, while NAD+ is dinucleotide coenzyme — not a peptide — different molecular classes with different handling consequences; they call for different primary diluents (sterile water (usp grade) versus sterile or bacteriostatic water); their leading degradation routes differ (deamidation at the asn-gly motif in the sequence for FOXO4-DRI, alkaline hydrolysis for NAD+), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.

FOXO4-DRI — origin

FOXO4-DRI was designed in the laboratory of Peter de Keizer (Erasmus University Medical Center) and published in Cell in 2017 (Baar et al.). It mimics the region of the transcription factor FOXO4 that binds p53, but is built from D-amino acids in reversed order — a retro-inverso design that keeps the side-chain layout while making the backbone unrecognisable to proteases. A cationic, arginine-rich tail derived from the HIV-TAT cell-penetrating sequence carries it into cells.

NAD+ — origin

NAD+ is not a peptide at all, and that single fact governs everything about how it is handled. It is a dinucleotide coenzyme — nicotinamide and adenine linked through a pyrophosphate bridge — present in every living cell and central to redox metabolism. It was first identified in 1906 by Arthur Harden as a small heat-stable factor required for yeast fermentation.

FOXO4-DRI research themes

FOXO4–p53 interaction in senescent cells

The founding study showed that senescent cells rely on FOXO4 holding p53 in the nucleus. Interfering with that interaction caused p53 nuclear exclusion and intrinsic apoptosis selectively in senescent cells in culture (Baar et al., Cell 2017).

Chemotoxicity and ageing mouse models

The same study examined doxorubicin-induced senescence, fast-ageing XpdTTD/TTD mice and naturally aged mice, reporting changes in fur density, fitness and renal markers.

Senescent Leydig cells

Studied in hydrogen-peroxide-induced senescent TM3 Leydig cells and aged mice for effects on the testicular microenvironment (Zhang et al., Aging 2020).

Expanded human chondrocytes

At 25 µM in vitro it removed a large share of late-passage (senescent-enriched) human chondrocytes while sparing early-passage cells, without improving cartilage-forming capacity (Huang et al., Front Bioeng Biotechnol 2021).

NAD+ research themes

Sirtuin activation

Sirtuins consume NAD+ as a co-substrate, which links cellular NAD+ availability directly to their activity.

Mitochondrial energy metabolism

Its canonical role as the central redox carrier of cellular respiration.

DNA repair via PARP

PARP enzymes consume NAD+ during DNA damage response, a heavily studied competing demand.

Age-related NAD+ decline

A major driver of current research interest: measured NAD+ levels fall with age across tissues in animal models.

FOXO4-DRI handling

  • Let the vial reach room temperature before opening.
  • Add diluent gently down the vial wall and swirl; do not vortex.
  • Use low-bind polypropylene rather than glass for dilutions — the cationic tail adsorbs to glass.
  • Protect solutions from light.

NAD+ handling

  • Allow the sealed vial to reach room temperature before opening — opening a cold vial of hygroscopic material condenses water directly onto it.
  • Keep solutions at or below neutral pH; alkaline conditions destroy NAD+ quickly.
  • Prepare fresh solutions where concentration accuracy is important rather than relying on stored stock.
  • Protect from light at all stages.

Both third-party tested

Every Popular Peptides batch of FOXO4-DRI and NAD+ is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.

Verify a batchPublished COAsHow we test

FOXO4-DRI reference

Full FOXO4-DRI reference FOXO4-DRI storage FOXO4-DRI reconstitution FOXO4-DRI calculatorFOXO4-DRI product details

NAD+ reference

Full NAD+ reference NAD+ storage NAD+ reconstitution NAD+ calculatorNAD+ product details

Related comparisons

5-Amino-1MQ vs FOXO4-DRI5-Amino-1MQ vs NAD+Cagrilintide vs NAD+CJC-1295 (No DAC) vs NAD+CJC-1295 + Ipamorelin vs NAD+DSIP vs FOXO4-DRIDSIP vs NAD+Epithalon vs FOXO4-DRI

FOXO4-DRI and NAD+ are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.